Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer

被引:0
作者
Bashir Al Hussein Al Awamlh
Sam S. Chang
机构
[1] Vanderbilt University Medical Center,Department of Urology
[2] A-1302 Medical Center Drive,undefined
[3] Vanderbilt Ingram Cancer Center,undefined
来源
Current Oncology Reports | 2023年 / 25卷
关键词
Non-muscle invasive bladder cancer; Intravesical chemotherapy; Carcinoma in situ of the bladder; BCG-unresponsive;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:83 / 91
页数:8
相关论文
共 183 条
[1]  
Cumberbatch MGK(2018)Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018 Eur Urol 74 784-795
[2]  
Jubber I(2022)Cancer statistics, 2022 CA Cancer J Clin 72 7-33
[3]  
Black PC(2019)European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 Update Eur Urol 76 639-657
[4]  
Esperto F(2016)Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline J Urol 196 1021-1029
[5]  
Figueroa JD(1999)Long-term followup of initial Ta grade 1 transitional cell carcinoma of the bladder J Urol 162 1946-1950
[6]  
Kamat AM(2012)Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guerin Eur Urol 62 118-125
[7]  
Siegel RL(2011)Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review Eur Urol 60 493-500
[8]  
Miller KD(2009)Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with Bacillus Calmette-Guerin: the CUETO scoring model J Urol 182 2195-2203
[9]  
Fuchs HE(2006)Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol. 49 466-5
[10]  
Jemal A(2001)A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer BJU Int 88 209-216